What the semaglutide weight-loss trials actually showed

Few drugs have reshaped a therapeutic category as quickly as semaglutide. But the headline numbers that circulate online flatten a more precise story — one written across a sequence of randomized trials with specific designs, doses, and endpoints. Here is what those trials actually reported.

The pivotal efficacy signal: STEP 1

In the STEP 1 trial, 1,961 adults with overweight or obesity and no diabetes received once-weekly semaglutide 2.4 mg or placebo alongside lifestyle counseling. At 68 weeks, the semaglutide group lost a mean of 14.9% of body weight versus 2.4% with placebo — a roughly 12.4-percentage-point difference.^[1] Around a third of treated participants lost at least 20% of their starting weight, a magnitude previously associated mainly with bariatric surgery.

What happens when you stop: STEP 4

Efficacy at 68 weeks does not answer the question patients actually ask — what happens after. STEP 4 addressed it directly. Participants who had already reached the 2.4 mg maintenance dose were randomized either to continue or to switch to placebo. Those who continued kept losing weight; those switched to placebo regained a substantial share of what they had lost, underscoring that semaglutide treats obesity as a chronic condition rather than curing it.^[2]

Beyond the scale: cardiovascular outcomes (SELECT)

The SELECT trial moved the conversation from weight to hard outcomes. Among more than 17,000 adults with established cardiovascular disease and obesity but without diabetes, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by about 20% (hazard ratio 0.80) over a mean follow-up of more than three years.^[3] It was the first evidence that a weight medication could change cardiovascular risk in this population — a finding that reframed semaglutide as a cardiometabolic therapy, not a cosmetic one.

For context: the tirzepatide comparison

Semaglutide's numbers are best read against its closest competitor. In SURMOUNT-1, the dual GIP/GLP-1 agonist tirzepatide produced mean weight reductions of up to roughly 20.9%at the highest (15 mg) dose over 72 weeks.^[4] The two agents have not been compared head-to-head for weight loss in a single pivotal obesity trial of identical design, so cross-trial comparisons should be read with appropriate caution — different populations, durations, and endpoints.

The honest bottom line

Semaglutide's weight-loss effect is large, real, and — critically — durable only while treatment continues. The cardiovascular benefit in SELECT is the strongest argument yet that the metabolic changes run deeper than the number on the scale. The open questions are about access, cost, long-term adherence, and how the effect holds across years rather than months.